US-Listed Biological Products, (No Diagnostic Substances) — Revenue Percentiles, FY 2021
Population: 132 US-listed companies (SIC 2836), fiscal year 2021; fiscal year ends 2021-06-30 to 2022-04-30.
Cite as: FACTANKER, https://factanker.com/industries/sic-2836/revenue/2021
Fiscal year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · latest
| 10th percentile | $0 |
|---|---|
| 25th percentile | $974.5k |
| Median | $13.6M |
| 75th percentile | $74.3M |
| 90th percentile | $470.3M |
| Mean | $758.2M |
| Minimum | $0 |
| Maximum | $27.3B |
Methodology & sources
Revenue as filed, one fiscal year per company; percentiles computed in the database via percentile_cont, never by a model. Fiscal year 2021 = fiscal years ending 2021-06-01 to 2022-05-31 (majority-overlap rule; June-ending fiscal years count toward the ending calendar year).
Source: SEC EDGAR filings (public domain). Data: FACTANKER registry, precomputed 2026-09-06.
Revenue as filed, one fiscal year per company; percentiles computed in the database via percentile_cont, never by a model. Fiscal year 2021 = fiscal years ending 2021-06-01 to 2022-05-31 (majority-overlap rule; June-ending fiscal years count toward the ending calendar year).
Source: SEC EDGAR filings (public domain). Data: FACTANKER registry, precomputed 2026-09-06.
Evidence samples
Latest Revenue percentiles (live) · All Biological Products, (No Diagnostic Substances) benchmarks · All industries